Objective: Darbepoetin can be administered either intravenously (i.v.) or subcutaneously (s.c.). However, no information is available regarding pharmacokinetics and pharmacodynamics following its i.v. administration to neonates.
Introduction
The darbepoetin molecule was created by biologically modifying recombinant erythropoietin (rEpo) in order to generate five carbohydrate-binding sites, compared with three in rEpo. This modification produced a more potent erythropoietic stimulator with the advantage of requiring less frequent dosing. 1, 2 We recently reported results of pharmacokinetic and pharmacodynamic studies following a single subcutaneous (s.c.) dose of darbepoetin to premature neonates. 3 Some neonates who might be treated with darbepoetin have a intravenous (i.v.) line in place, and for these patients perhaps i.v. administration would be a potential route. Subcutaneous dosing of darbepoetin is not reported, in adults, as particularly painful, but reducing pain experienced by neonates in the intensive care setting is an important issue and led us to explore the possibility of i.v. rather than s.c. dosing of darbepoetin. However, no information is available regarding the pharmacokinetics or pharmacodynamics of darbepoetin administered i.v. to neonates. To obtain this information, we enrolled 10 neonatal intensive care unit (NICU) patients into a study where they received a single dose of darbepoetin through an existing i.v.
Materials and methods

Patient eligibility
Neonates were eligible if they had an i.v. in place and had a hemoglobin of p10.5 g/dl. Because of laboratory variability, we permitted study entry of patients whose hemoglobin was recorded as high as 10.7 g/dl. Patients were ineligible if they were judged by the attending neonatologist as being too ill to participate in a research study, such as requiring mechanical ventilation with more than 50% inspired oxygen, or requiring vasopressors to elevate the blood pressure. Patients were also ineligible if the attending neonatologist judged they would probably need a blood transfusion in the next few days. Baseline reticulocyte count was not used as a criterion for eligibility.
Study design
Study subjects received a single 4 mg/kg dose of darbepoetin (Aranesp, Amgen Inc., Thousand Oaks, CA) i.v. in normal saline, using a 4-h constant infusion. Blood was drawn before the dose, and 48 h after, for immature reticulocyte fraction (IRF) and absolute reticulocyte count (ARC). In addition, blood was drawn before the dose and 30 min, 4, 24 and 48 h after the completion of the infusion for pharmacokinetic analysis. The amount of each study phlebotomy was 0.4 ml for the IRF and ARC, and an additional 0.6 ml for the plasma Epo concentration. The Institutional Review Board of Intermountain Health Care approved the study and the parents of each study participant signed informed consent.
Laboratory studies
The IRF and the ARC were determined using the Beckman Coulter GENS System (Beckman Coulter Inc., Brea, CA). The IRF assesses reticulocyte maturity based on staining intensity of reticulocytes, which is proportional to RNA content. 4 The ARC was calculated automatically by multiplying the erythrocyte concentration by the reticulocyte percentage. Plasma Epo concentrations were quantified by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN). The ELISA measures darbepoetin as well as erythropoietin. The minimum detectable concentration was 0.6 mU/ml, with inter-and intra-assays within 5% (2.8-4.9%).
Pharmacokinetic analysis
For purposes of data analysis, the neonates delivered p32 weeks gestation were classified as 'preterm' (n ¼ 7) and those >32 weeks were classified as 'term or near term'. Pharmacokinetic parameters were determined using a one exponential disposition kinetics model ('one-compartment model') in all 10 subjects. In two subjects, the data were not explained well by a one exponential disposition, so these two were fitted using a two exponential disposition ('two-compartment model'). Kinetic parameters were obtained using the interactive program WINFUNFIT, a windows version evolved from the general non-linear regression program FUNFIT. 5 The half-life of darbepoetin was calculated as the reciprocal of the a parameter (or the smallest a parameter when n ¼ 2) multiplied by ln 2 ¼ 0.6931. The parameter values were reported from the pooled data, whereas the range given for the pharmacokinetic parameters were based on fits to individual data. The area under the curve (AUC) reported for the darbepoetin plasma level response and the AUC for the absolute reticulocyte versus time response were also based on the pooled data, whereas the range given is for the individual determinations. In our calculations, we used a conversion of 400 U Epo ¼ 1 mg darbepoetin, consistent with our previous study and manufacture labeling.
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Statistical considerations Descriptive statistics were calculated using S-Plus version 7.0 (Insightful Corporation, Seattle, WA). Means and s.d. were used to express values in groups that were normally distributed, and median and range to express values in groups that were not. A Fisher exact test (UCLA Statistics, Los Angeles, CA) was used to assess whether the IRF and the ARC had increased 48 h after darbepoetin administration.
Results
Between July 2005 and November 2005, the families of 12 eligible NICU patients not previously enrolled in a conflicting research study were contacted regarding participating in this study. Consent was granted for all 12. One patient did not receive the dose of darbepoetin, but received an erythrocyte transfusion before the dose was to be given. One patient received the dose of darbepoetin as scheduled, but inadvertently the IRF and ARC were drawn but not run. The remaining 10 patients received the dose of darbepoetin as stipulated by the study protocol and received all the scheduled study-related blood tests. None of the 10 study subjects dropped out of the study. The demographics of the study subjects are shown in Table 1 .
No adverse events were reported on any of the 10 subjects. No new rashes and no increase or decrease in blood pressure, heart rate or need for supplemental oxygen was observed in relation to the doses. Table 2 lists the IRF and ARC before and 48 h after the dosing. As a group, the IRF and ARC were not significantly higher 48 h after dosing than they had been before dosing (Figure 1) . Three of the subjects had reticulocyte counts >200 000/ml immediately before the darbepoetin dose was given, whereas seven had lower counts. Among those with the lower baseline reticulocyte counts, the IRF and ARC were generally higher 48 h after dosing (Pp0.05), but among those with higher baseline counts, no elevations were seen at 48 h.
Pharmacokinetic parameters for the 10 subjects are shown in Table 3 . The volume of distribution was 0.77 l/kg, the darbepoetin clearance was 52.8 ml/h/kg and the (terminal) t 1/2 was 10.1 h. Seven of the subjects were preterm neonates (Table 4) . In these seven, we found no significant correlation between gestational age or age at darbepoetin administration and pharmacokinetic parameters. Three of the subjects were term or near-term neonates. In these three, the anemia was probably the result of phlebotomy losses. One of these (patient 4) had endocarditis with vegetations on the tricuspid valve. The other two (patients 5 and 6) had pneumonia and ventilatory failure. In the three-term and nearterm neonates, the volume of distribution significantly correlated with both gestational age and age at darbepoetin administration.
Discussion
When administered SC to adults, darbepoetin has a t 1/2 of 49 h, but when given i.v. to adults, the t 1/2 is considerably shorter; only 25 h. 7 We previously reported that when 4 mg/kg darbepoetin was administered s.c. to neonates, darbepoetin had a t 1/2 of 21.5 h. 3 In the present study, when given i.v. to neonates, the t 1/2 was much shorter, 10.1 h. The longer t 1/2 after s.c. dosing than after i.v. dosing, in both adults and neonates, is probably owing to slower release of drug into the circulation from the s.c. injection site. However, the overall shorter t 1/2 in neonates, for both s.c. and i.v. dosing, suggests two basic differences in the way the drug is handled in neonates. First, neonates have more rapid plasma clearance of darbepoetin and a much larger volume of distribution. These features might be owing to the presence of more Epobinding sites, the expression of Epo-binding sites on more tissues or more avid Epo binding. These explanations are consistent with the widespread expression of Epo receptors on non-erythropoietic tissues in the fetus. 8, 9 Second, the release of darbepoetin from the s.c. injection site might be more rapid in neonates than it is in adults. 3 Only three previous reports have described darbepoetin administration to children.
3,10,11 Lerner et al. 10 studied 12 children aged 3-16 years with chronic renal disease, and found that the t 1/2 after s.c. dosing (43 h) and after i.v. dosing (22 h) was similar to those in adults. Similarly, we observed an approximately twofold longer half-life after s.c. administration than after i.v. administration of the same dose. However, in neonates, we measured a much shorter t 1/2 , a larger volume of distribution and more rapid clearance than previously reported in children. De Palo et al.
11 studied seven children ages 7-15 undergoing hemodialysis, and found the drug to be effective but did not report pharmacokinetic parameters. We previously administered either 1 or 4 mg/kg s.c. to 12 neonates and found the larger dose was more effective in rapidly increasing the IRF and ARC. We found that clearance was highly variable in both the s.c. and i.v. dosing.
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The calculation 'AUC retic ' represents the erythropoietic activity from darbepoetin. Owing to the non-selective nature of the plasma assay, which does not differentiate between darbepoetin and endogenous erythropoietin, it is not possible to accurately determine AUC darbepoetin . However, the comparatively low baseline values of Epo in these subjects render the AUC Epo (Table 4 ) a very good approximation for the AUC darbepoetin. The ratio AUC retic /AUC Epo (Table 4) indicates a relationship between darbepoetin concentration in plasma and corresponding erythropoietic activity.
Although not directly tested in the present study, or in any other published report, it might be that darbepoetin administered i.v. to neonates is less effective at stimulating erythropoiesis than is darbepoetin administered s.c. This speculation is based on the higher and more consistent increases in IRF and ARC in our previous study, 3 where the dose was given s.c., compared with the present study where the dose was given i.v. This speculation is supported further by the lower value of the AUC retic /AUC Epo after i.v. dosing compared to our previous s.c. dosing study. This is owing to the lower value for AUC retic after i.v. dosing, whereas the AUC Epo is comparable to the value we obtained after s.c. administration. 3 Admittedly, we only followed IRF and ARC for 48 h in this study, and perhaps significant increases occurred after that time. However, our findings lead us to speculate that i.v. administration, even when infused over a prolonged time such as the 4-h infusion we tested, results in very high circulating concentrations that eventuate in substantial loss of darbepoetin into the urine. 12 This pilot study involved few patients and the gestational range was large, making the conclusions less certain. As larger studies are devised to test darbepoetin administration in the NICU, many important issues remain to be addressed. Whether s.c. dosing is more effective than i.v. dosing, and whether effectiveness correlates with gestational age are two such issues. Whether beneficial effects occur in neurodevelopment 13 and NEC reduction, 14 as suggested by retrospective studies, on the basis of Epo receptors on neurons and enterocytes, are other important issues. Abbreviations: AUC retic ¼ area under the curve for the absolute reticulocyte count versus time response (see Figure 1) ; AUC Epo ¼ area under the curve for the baseline-corrected erythropoietin plasma level versus time (see Figure 1) . Values in parenthesis are ranges.
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